A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors

NCT01731925 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Carcinoid Tumors

Interventions

DRUG: Lanreotide
DRUG: Placebo (for sunitinib)
DRUG: Sunitinib

Sponsor

GERCOR - Multidisciplinary Oncology Cooperative Group

Collaborators

[object Object]
[object Object]